RNU7-13P: A Promising Drug Target / Biomarker (G100147761)

Target Name: RNU7-13P

NCBI ID: G100147761

RNU7-13P

Other Name(s): U7.13 | RNA, U7 small nuclear 13 pseudogene

RNU7-13P: A Promising Drug Target / Biomarker

The use of RNA interference (RNAi) technology has revolutionized the field of genetics and gene therapy. RNAU7-13P is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases, including cancer. In this article, we will explore the biology and potential applications of RNAU7-13P, and discuss its potential as a drug target or biomarker.

Structure and Function

RNAU7-13P is a non-coding RNA molecule that is expressed in various tissues and cells of the body. It is characterized by a 7-nt stem-loop region at its start and a 13-nt terminal region. RNAU7-13P has been shown to play a role in regulating gene expression in various cell types, including cancer cells.

One of the most significant features of RNAU7-13P is its ability to interact with specific RNA binding proteins, known as RNA-proteins. These proteins are responsible for bringing RNA molecules to their target tissues or cells, where they can then interact with the RNA molecule to regulate gene expression. RNAU7-13P has been shown to interact with several different RNA-proteins, including the protein called SNAPK.

SNAPK is a RNA-protein that is involved in the regulation of gene expression in various cell types. It has been shown to interact with RNAU7-13P, and this interaction may play a role in the regulation of gene expression in cells.

Potential Applications

RNAU7-13P has the potential to be a drug target or biomarker for several diseases, including cancer. One of the most promising applications of RNAU7-13P is its ability to interact with SNAPK, a protein that is involved in the regulation of gene expression in various cell types. This interaction may play a role in the regulation of gene expression in cells, including cancer cells.

RNAU7-13P may also be a useful biomarker for the diagnosis and monitoring of cancer. The expression of RNAU7-13P has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This may suggest that RNAU7-13P could be a useful biomarker for the diagnosis and monitoring of cancer.

RNAU7-13P may also have potential applications as a drug target for diseases that are caused by the regulation of gene expression. For example, RNAU7-13P has been shown to interact with the protein called USP90, which is involved in the regulation of gene expression in various cell types. This interaction may play a role in the regulation of gene expression in cells, including those that are affected by diseases caused by the regulation of gene expression.

Conclusion

RNAU7-13P is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases, including cancer. Its ability to interact with SNAPK and other RNA-proteins suggests that it may play a role in the regulation of gene expression in various cell types. RNAU7-13P may also be a useful biomarker for the diagnosis and monitoring of cancer, as well as a potential drug target for diseases caused by the regulation of gene expression. Further research is needed to fully understand the role of RNAU7-13P in these processes.

Protein Name: RNA, U7 Small Nuclear 13 Pseudogene

The "RNU7-13P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU7-13P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets